|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Potent activity of ponatinib(AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies 显示文摘 | GOZGIT JM WONG M J WARDWELL S | 2011 | Mol Cancer Ther2011，10，6： | 1 |
| 2 | Use of an aggressive MCF-7 cell line variant , TMX2-28, to study cell invasion in breast cancer显示文摘 | Gozgit JM Pentecost BT Marconi SA | 2006 | Mol Cancer Res2006，4，12： | 1 |
| 3 | Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR- amplified or mutated cancer models 显示文摘 | GOZGIT JM WONG M J MORAN L | 2012 | Mol Cancer Ther2012，11，3： | 1 |
| 4 | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models显示文摘 | GOZGIT JM SQUILLACE RM WONGCHENKO MJ | 2013 | Cancer Chemother Pharmacol2013，71，5： | 1 |
| 5 | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models显示文摘 | Gozgit JM Squillace RM Wongchenko MJ | 2013 | Cancer Chemother Pharmacol2013，71，： | 1 |
| 6 | Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2显示文摘 | Gozgit JM Bebernitz G Patil P | 2008 | J Biol Chem2008，283，32： | 1 |
| 7 | SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSerlOp27) in triple-negative breast cancer 显示文摘 | Fagan-Solis KD Pentecost BT Gozgit JM | 2014 | J Cell Physiol2014，229，9： | 1 |
| 8 | Com- bined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models显示文摘 | Gozgit JM Squillace RM Wongchenko MJ | 2013 | CancerChemother Pharmacol2013，71，5： | 1 |
| 9 | Combined targeting of FGFR2 and m TOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models显示文摘 | Gozgit JM Squillace RM Wongchenko MJ | 2013 | Cancer Chemother Pharmacol2013，71，5： | 1 |
| 10 | PLD1 is overex- pressed in an ER negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas显示文摘 | Gozgit JM Pentecost BT Marconi SA | 2007 | Br J Cancer2007，97，6： | 1 |
| 11 | Combined targeting of FGFR2 and m TOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models显示文摘 | Gozgit JM Squillace RM Wongchenko MJ | 2013 | Cancer Chem Pharmacol2013，71，5： | 1 |
| 12 | Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer 显示文摘 | Gozgit JM Pentecost BT Marconi SA | 2006 | Mol Cancer Res2006，4，12： | 1 |
| 13 | Use of an aggressive MCF-7 cell line variant,TMX2-28,to study cell invasion in breast cancer显示文摘 | Gozgit JM Pentecost BT Marconi SA | 2006 | Mol Cancer Res2006，4，12： | 1 |
| 14 | Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models显示文摘 | Gozgit JM Wong MJ Moran L | 2012 | Mol Cancer Ther2012，11，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员